Zions Bancorporation N.A. Raises Holdings in AstraZeneca PLC (NASDAQ:AZN)

Zions Bancorporation N.A. grew its stake in AstraZeneca PLC (NASDAQ:AZN) by 36.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,332 shares of the company’s stock after acquiring an additional 3,272 shares during the quarter. Zions Bancorporation N.A.’s holdings in AstraZeneca were worth $961,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. McClarren Financial Advisors Inc. boosted its position in AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after purchasing an additional 247 shares in the last quarter. GHP Investment Advisors Inc. purchased a new stake in AstraZeneca during the second quarter worth about $26,000. Capital Performance Advisors LLP acquired a new position in shares of AstraZeneca during the third quarter worth about $28,000. Pathway Financial Advisers LLC acquired a new stake in shares of AstraZeneca during the 1st quarter worth about $29,000. Finally, Hobbs Group Advisors LLC acquired a new stake in shares of AstraZeneca during the second quarter worth about $35,000. 20.35% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently issued reports on AZN shares. TD Cowen raised their price target on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Trading Down 0.4 %

Shares of AZN stock opened at $65.04 on Friday. The company has a quick ratio of 0.69, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $201.66 billion, a P/E ratio of 31.12, a P/E/G ratio of 1.21 and a beta of 0.47. The stock has a 50-day simple moving average of $75.79 and a 200 day simple moving average of $78.38. AstraZeneca PLC has a fifty-two week low of $60.47 and a fifty-two week high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The business had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the previous year, the company posted $0.87 earnings per share. AstraZeneca’s revenue for the quarter was up 18.0% compared to the same quarter last year. On average, sell-side analysts expect that AstraZeneca PLC will post 4.07 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.